Performance Study of a Non-invasive Glucose Monitoring Device Prototype
NCT ID: NCT03519841
Last Updated: 2020-10-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
6 participants
INTERVENTIONAL
2018-04-13
2018-10-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Performance Characteristics of Non-invasive Glucose Monitoring Device Prototypes
NCT04021251
Study of a Novel Non-invasive Glucose Monitoring Device
NCT03782441
Performance Characteristics and Safety Assessment of a Non-invasive Glucose Monitoring Device
NCT03352518
Study of a Non-invasive Glucose Measuring Device
NCT05851469
Performance Evaluation of a Novel Non-invasive Glucometer, Calibrated Against Validated Interstitial Glucose References
NCT03782649
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Part A) Subjects will collect spectral Raman data on device every 15 minutes for 10 hours a day for five days. The five days will be distributed within a timeframe of ten days. A Flash Glucose Monitor will be used as a comparator. In addition to this, four daily capillary Blood Glucose readings will be collected.
Part B) Subjects will perform four daily measuring sessions in which optical Raman readings are paired with capillary Blood Glucose comparator. Measuring sessions are performed in subjects' own home while maintaining usual diabetes management routines. Subjects will collect data for 30 days during a 60 days' period.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DEVICE_FEASIBILITY
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
RSP-13-01
Experimental: IMD data collection Subjects will intensively collect spectral Raman data on P0.1 in a home-based setting for 5 days. Data will be paired with reference measurements.
P0.1
Investigational Medical Device collecting spectral Raman data from tissue.
RSP-13-02
Experimental: IMD data collection Subjects will collect spectral Raman data on P0.1 during four measuring sessions a day for 30 days distributed over a time period of 60 days. Each timepoint is conducted in duplicate. Spectral data will be compared to standard BG measurements.
P0.1
Investigational Medical Device collecting spectral Raman data from tissue.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
P0.1
Investigational Medical Device collecting spectral Raman data from tissue.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diabetic patients (all types), insulin requiring
* Skin phototype 1-4
Exclusion Criteria
* For female participants: Breastfeeding
* Subjects not able to understand and read Danish
* In Investigator's opinion, subject is not able to follow instructions as specified in the protocol
* Rejection by optical screenings
* Participants not able to hold hand/arm steadily (including tremors and Parkinson's Disease)
* Diagnosed with reduced circulation
* Extensive skin changes, tattoos or diseases on probe application site
* Known allergy to medical grade alcohol
* Known allergy to adhesives, applicable to subjects in RSP-13-01
* Systemic or topical administration of glucocorticoids for the past 7 days
* Subjects undergoing dialysis treatment
* Medical history or any condition that may, in the opinion of the Investigator, compromise the subject's ability to participate
* Concomitant medical condition which could present a risk to the safety or welfare of the subject or study staff.
* Participants currently enrolled in another study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
RSP Systems A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jan Erik Henriksen, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Steno Diabetes Center Odense, Denmark
Vibe Vestergaard, Nurse
Role: PRINCIPAL_INVESTIGATOR
Steno Diabetes Center Odense, Denmark
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Steno Diabetes Center Odense
Odense, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RSP-13
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.